Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7291054 | 1.00 | KEAP1 (0.50) | KEAP1SMN1; SMN2PAOXHPGDDUSP3 | |
| SCHEMBL7283905 | 1.00 | KEAP1 (0.50) | KEAP1SMN1; SMN2PAOXHPGDDUSP3 | |
| SCHEMBL7294030 | 1.00 | KEAP1 (0.50) | KEAP1SMN1; SMN2PAOXHPGDDUSP3 | |
| SCHEMBL7381439 | 1.00 | KEAP1 (0.50) | KEAP1SMN1; SMN2PAOXHPGDDUSP3 | |
| SCHEMBL6764986 | 1.00 | KEAP1 (0.50) | KEAP1SMN1; SMN2PAOXHPGDDUSP3 | |
| SCHEMBL7291045 | 0.98 | KEAP1 (0.52) | KEAP1SMN1; SMN2PAOXHPGDDUSP3 | |
| SCHEMBL1446165 | 0.92 | KEAP1 (0.54) | KEAP1SMN1; SMN2PAOXHPGDDUSP3 | |
| SCHEMBL986238 | 0.85 | HRH3 (0.46) | PAOXHIF1A | |
| SCHEMBL984275 | 0.85 | HRH3 (0.46) | PAOXHIF1A | |
| SCHEMBL425926 | 0.83 | GLA (0.47) | KEAP1SMN1; SMN2PAOXHPGDDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8221771-B2 | Formulations containing an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-5401722-A | Peptide analogues | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-03-28 | — | — | US | disclosed |
| US-5378691-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | disclosed |
| US-5328916-A | Renin inhibitors, hypotensive agents | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-07-12 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5147857-A | Enzyme inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1992-09-15 | — | — | US | disclosed |
| EP-0501280-A2 | Renin-inhibiting peptide analogues | MERCK PATENT GmbH (DE) | 1992-09-02 | — | — | EP | disclosed |
| EP-0499080-A2 | Aminoacid derivatibes | MERCK PATENT GmbH (DE) | 1992-08-19 | — | — | EP | disclosed |
| EP-0490259-A2 | Aminoacid and peptid derivatives with renin inhibiting properties | MERCK PATENT GmbH (DE) | 1992-06-17 | — | — | EP | disclosed |
| EP-0481311-A2 | Aminoacid derivatives | MERCK PATENT GmbH (DE) | 1992-04-22 | — | — | EP | disclosed |
| EP-0474008-A1 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1992-03-11 | — | — | EP | disclosed |
| EP-0464517-A2 | Amino acid derivatives with renin inhibiting activity | MERCK PATENT GmbH (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0456039-A2 | Renin inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1991-11-13 | — | — | EP | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0446751-A1 | Glycolic acid derivatives | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | IFNG, IRF3, ICOS | KEAP1 448/4885SMN1; SMN2 3797/4885PAOX 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.